Association between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants: population-based cohort study.

ABSTRACT:

Background

Thromboembolism has been reported as a consequence of severe COVID-19. Although warfarin is a commonly used anticoagulant, it acts by antagonising vitamin K, which is low in patients with severe COVID-19. To date, the clinical evidence on the impact of regular use of warfarin on COVID-19-related thromboembolism is lacking.

Methods

On behalf of NHS England, we conducted a population-based cohort study investigating the association between warfarin and COVID-19 outcomes compared with direct oral anticoagulants (DOACs). We used the OpenSAFELY platform to analyse primary care data and pseudonymously linked SARS-CoV-2 antigen testing data, hospital admissions and death records from England. We used Cox regression to estimate hazard ratios (HRs) for COVID-19-related out

SUBMITTER: OpenSAFELY Collaborative 

PROVIDER: S-EPMC8525065 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature